GE Healthcare and Lantheus Medical Imaging have launched a second phase III clinical trial for Lantheus' flurpiridaz F-18 investigational PET radiopharmaceutical.
Called the AURORA study, the international multicenter trial will evaluate the diagnostic efficacy of flurpiridaz F-18 injection PET myocardial perfusion imaging (MPI) for detecting coronary artery disease (CAD). The prospective, open-label study will enroll patients with suspected CAD for whom an intracoronary angiography has been indicated. These patients will undergo SPECT MPI and flurpiridaz F-18 injection PET MPI prior to receiving coronary angiography.
The study's primary end point will be the diagnostic performance of flurpiridaz F-18 injection PET MPI for detecting significant CAD, according to the vendors. The first patient was enrolled in June, and a total of 650 will be included in the trial. The companies project that the last patient follow-up will be completed in August 2020.
